Drug Profile
Enoblituzumab - MacroGenics
Alternative Names: Anti-B7-H3 mAb; MGA-271; TJ-271Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer I-MAB Biopharma; MacroGenics; Masonic Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Malignant melanoma; Squamous cell cancer; Urogenital cancer
Most Recent Events
- 16 Feb 2024 MacroGenics initiates enrolment in phase-II HEAT trial for Adenocarcinoma (Neoadjuvant therapy, Mid-stage disease) in USA (IV) (NCT06014255)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)